Teva Pharmaceutical Industries (TEVA) Minority Interest (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Minority Interest across 18 years of filings, most recently posting $4.0 million for Q1 2026.

• Quarterly Minority Interest fell 42.86% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 42.86% YoY) and the FY2025 annual result came in at $4.0 million, down 98.82% from the prior year.
• Minority Interest steadied at $4.0 million in Q1 2026, from $4.0 million in the prior quarter.
• Over five years, Minority Interest peaked at $916.0 million in Q1 2022 and troughed at $4.0 million in Q4 2025.
• A 5-year average of $456.0 million and a median of $461.0 million in 2023 frame the typical range for Minority Interest.
• Annual changes were most pronounced in 2022 — Minority Interest decreased 6.05% — and 2025, when it slumped 98.82%.
• Tracing TEVA's Minority Interest over 5 years: stood at $794.0 million in 2022, then fell by 26.7% to $582.0 million in 2023, then sank by 41.58% to $340.0 million in 2024, then sank by 98.82% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
• Business Quant data shows TEVA's Minority Interest at $4.0 million in Q1 2026, $4.0 million in Q4 2025, and $7.0 million in Q1 2025.